Quad/Graphics, Inc. has a 12 month low of $4.06 and a 12 month high of $9.13. The company has a 50 day simple moving average of $5.34 and a two-hundred day simple moving average of $6.40.

Well, we could find out. Regeneron's purchase is still subject to court approval. If it gets a green light, as expected, the company could gain access to genetic data from more than 15 million ...

Continue » Regeneron's purchase is still subject to court approval. If it gets a green light, as expected, the company could gain access to genetic data from more than 15 million 23andMe ...

Regeneron Pharmaceuticals acquiring genetic testing firm 23andMe for $256 million. The deal follows 23andMe’s Chapter 11 bankruptcy protection filing in March. Transaction excludes telehealth ...

A biotech future built on data: Regeneron’s acquisition of 23andMe blurs the line between pharmaceutical innovation and genetic surveillance. Unsplash+ “We are pleased to have reached a ...

Regeneron Pharmaceuticals is purchasing genetics and biotechnology company 23andMe and has vowed to protect customer data while continuing genome testing services. Regeneron announced the purchase ...

Regeneron Pharmaceuticals has agreed to acquire 23andMe’s consumer genetics business and assets for $256 million, following 23andMe’s Chapter 11 bankruptcy. GOP Calls for Investigation into ...

Regeneron Pharmaceuticals said in a press release yesterday that it would acquire 23andMe’s Personal Genome Service (PGS), Total Health and Research Services business lines, alongside its Biobank and ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...